Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase I primary endpoint met in phase I/II study of NC-6300

Dec. 14, 2018

Seliforant shown not to affect vigilance, cognitive performance during motion stimulus

Dec. 14, 2018

Protagonist begins phase I study of PN-10943 for inflammatory bowel disease

Dec. 14, 2018

Chinese researchers divulge RORC antagonists

Dec. 14, 2018

Ono Pharmaceutical identifies new prostanoid EP4 receptor antagonists

Dec. 14, 2018

Cancer Research Technology discovers BCL-6 inhibitors

Dec. 14, 2018

Czech Academy of Sciences institutes patent PGE2 production inhibitors

Dec. 14, 2018

Targeting alpha-synuclein can mitigate stroke damage

Dec. 14, 2018

Mutation in orexin receptor is associated with panic disorder development and response to therapy

Dec. 14, 2018

Virginia Tech collaborates with NIH to study ML-351 for chronic pain

Dec. 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...